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Background: Mycobacterium kansasii infection is one of the most common causes of nontuber-
culous mycobacterial lung disease in the world. However, it is not possible to differentiate
completely between M. kansasii and other nontuberculous mycobacteria (NTM) because of
a lack of direct comparative studies. This retrospective study sought to identify their clinical
and radiological features systematically.
Methods: The sample included 98 consecutive patients with a culture-positive diagnosis of NTM
infection, derived from the databases of the Laboratory of Microbiology of a tertiary medical
center and two outpatient tuberculosis centers. Sixty-four patients had M. kansasii infection.
All patients fulfilled disease criteria for treatment. Data on patient background and clinical
features were collected, and chest radiographs were evaluated.
Results: In the M. kansasii group, n Z 27 (42%) were native-born Israelis compared to 9.4%
(n Z 3) of all other NTM groups (p Z 0.0001). Similar rates of co-morbid diseases, including
diabetes mellitus, heart disease, lung diseases, and malignancy were noted in both groups.
Old TB was less common in the M. kansasii group compared to the other NTM (3.1% vs.
23.5%, pZ 0.003). Clinical symptoms were significantly more common in patients with M. kan-
sasii infection. On radiological study, M. kansasii infection was associated with more cavita-
tions and unilaterality. Patients with M. kansasii infection had a higher likelihood of right
upper lobe disease (p Z 0.001). Pleural effusions and lymphadenopathy were found only in
a few patients in each group.
Conclusion: Major differences in the epidemiologic and clinical features of M. kansasii infec-
tion and other NTM have important diagnostic and clinical implications.
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Mycobacterium kansasii versus other NTM 1473Introduction infecting organism and the clinical findings independently
read the chest radiographs taken within 2 weeks of diag-Nontuberculous mycobacteria (NTM) have been identified
in clinical specimens as early as 1885. However, their
pathogenic role in humans was long overshadowed by that
of Mycobacterium tuberculosis. With recent improvements
in techniques for isolating and identifying mycobacteria
and controlling tuberculosis, the importance of NTM,
especially in immunocompromised hosts, has been
recognized.
Mycobacterium kansasii has traditionally been considered
themost virulent of theNTM.1,2 It is the secondmost common
NTM after Mycobacterium avium complex and is one of the
common causes of NTM lung disease in the UK and western
Europe.2e5 M. kansasii infection likely occurs via an aerosol
route. Tap water is a major reservoir and the only environ-
mental (water or soil) source of the bacterium identified to
date.6,7 However, isolation ofM. kansasii from tap water can
be intermittent, which might explain why some investigators
failed to recover it from this source. Risk factors for M. kan-
sasii infection include chronic lung disease, previous myco-
bacterial disease, malignancy, and alcoholism.2,7e12 In
immunocompetent patients, pulmonary disease is the most
frequent clinical manifestation,7 although approximately
40% have no associated illness.2 When the infection is treated
appropriately, outcome is good.13e16
The major clinical and therapeutic implications of infec-
tion with these pathogens and their diverse prevalence in
different countries warrant ongoing surveillance of species
distribution of mycobacterium isolates. Furthermore, to the
best of our knowledge, there are no systematic studies
comparing theclinical and radiological features ofM.kansasii
with other NTM infections, which was the goal of this study.
Patients and methods
Patients and setting
All patients from whom a sputum specimen had grown NTM
between April 2007 and April 2010 were identified from the
Tuberculosis Clinic database of the tuberculosis centers in
the cities of Tel Aviv and Rehovot. These centers are part of
the Pulmonary Institute of Meir Medical Center that is
affiliated with the Sackler Faculty of Medicine, Tel Aviv
University, Tel Aviv, Israel. Data on the clinical features of
the patients (including systemic co-morbid disease and
smoking status), radiological findings, and outcome were
abstracted from the case notes and laboratory records by
a single investigator.
Patients for whom there was a high clinical suspicion of
tuberculosis, but negative sputum smears underwent
bronchoscopy with bronchoalveolar lavage and trans-
bronchial biopsy to confirm the diagnosis. All patients ful-
filled disease criteria for treatment according to the
American Thoracic Society (ATS) guidelines, as follows:
appropriate symptomatology, compatible radiographic
abnormalities, and culture-positive respiratory
specimens.17,18
All patients were tested for human immunodeficiency
virus (HIV). Two radiologists who were blinded to thenosis of mycobacterial disease. The radiographs were
assessed for previous or co-existent lung disease, site of
abnormality, loss of lung volume, air space shadowing,
circumscribed opacities and cavitations, bronchopulmonary
spread, local pleural disease, pleural effusions, lymphade-
nopathy, and evidence of a primary focus. Patients with
fibrotic changes in the left or right upper lobes or clinical
history of TB were diagnosed as having old tuberculosis.
The study was approved by the Ethics Committee of
Maccabi Medical Service, Tel Aviv, Israel.
Media
Sputum smears stained with auramine were examined by
fluorescent microscopy and the presence of acid-fast
organisms was confirmed with Ziehl-Neelsen stain. All
mycobacterial isolates were referred to the Public Health
Laboratory Mycobacterial Reference Unit at Abo Cabir for
identification and sensitivity testing.
The solid L-J medium (Heipha Diagnostika Biotest,
Germany) was applied to all specimens. The liquid medium
used during the first period consisted of 12B bottles con-
taining radio labeled Middlebrook 7H12 broth using the
Bactec 460 TB (Becton Dickinson, Franklin Lakes, NJ, USA)
system. Before use, the broth was supplemented with
polymyxin B, amphotericin B, nalidixic acid, trimethoprim
and azlocillin (PANTA). The liquid medium used during the
second period contained modified Middlebrook 7H9 broth
base, supplemented with PANTA before use in the MGIT 960
Mycobacteria Growth Indicator Tube (Becton Dickinson,
Franklin Lakes, NJ, USA). All media were inoculated in
duplicate and incubated in parallel at 30 C and 37 C for 8
weeks.
Isolates of acid fast bacilli were identified as M. tuber-
culosis, M. kansasii, MAC, or other NTM by conventional
biochemical reactions1,2 and AccuProbe culture confirma-
tion kits (Gen-Probe, San Diego, CA, USA). Mycobacterium
simiae was identified by photochromogenicity, positive
niacin, negative nitrate reduction, and TWEEN hydrolysis.
The resistance ratio method was used to test the
susceptibility strains to all the drugs mentioned and not the
MIC method.19 This method is based on the growth of the
tested strain relative to a standard sensitive (control) strain
at five standard doubled drug concentrations. We calcu-
lated the resistance ratio of each test strain to each drug by
dividing the minimum inhibitory concentration of the test
by the model minimum inhibitory concentration. As
doubling dilutions are used, the resistance ratio is 1 (or
less), 2, 3, 4, or 8. Strains with a resistance ratio of 1 or 2
are reported as susceptible, those with a resistance ratio of
4 are resistant, and those with a resistance ratio of 8 are
highly resistant.
Statistical analysis
Results are shown as mean  standard deviation. To
analyze between group differences in categorical variables,
chi-square test or Fisher’s exact test was used, as
1474 A. Matveychuk et al.appropriate. Pearson correlation coefficient (r) and its
significance (p) were calculated between the variables. A
p-value of 0.05 or less was considered statistically
significant.
Results
Clinical characteristics
The study population included 64 patients with M. kansasii
and 34 patients with other NTM. The most common NTM in
the non-M. kansasii group was MAC (14 patients) followed
by M. simiae (8 patients), Mycobacterium abscesus (5
patients), Mycobacterium gordonae (4 patients) and
Mycobacterium chelonae (3 patients). The baseline char-
acteristics of the patients are shown in Table 1. The mean
age of the 64 patients with M. kansasii infection was
44  19 (range 19e87) years; 23 (36%) were women. The
mean age of the 34 patients with infected with other NTM
infections was 63  13 (range 51e85) years and 14 (41%)
were women. The age differences were statistically
significant (p Z 0.0001).
Of the patients in the M. kansasii group, 42% were born
in Israel; most of the remaining patients were immigrantsTable 1 Clinical characteristics and symptoms at presentation
mycobacteria.
M. kansasii N
Age (yr)a 44  19
Sex
Male 41 (64)
Female 23 (36)
Origin
Israel 27 (42)
Former USSR 20 (31)
Ethiopia 3 (5)
Other 14 (22)
Smoker 23 (36)
Alcohol intake (>14 units/week) 3 (5)
Drug abuse 0 (0)
Symptoms at presentation
Chest pain 47 (74)
Cough 53 (86)
Hemoptysis 27 (42)
Weight loss 20 (32)
Sweats/Fever 25 (39)
Diagnosis by bronchoscopy 8 (13)
Comorbid conditions
Chronic liver disease 2 (3.1)
Diabetes 1 (1.6)
Cardiac disease 3 (4.7)
Malignancy 0 (0)
Chronic obstructive pulmonary disease 7 (10.9)
Bronchiectasis 8 (12.5)
Old Tuberculosis 2 (3.1)
Drug addiction 4 (6.2)
Use of immunosuppressive medication 1 (1.6)
Bold values signify P  0.05.
a MeanSD. All other values are n (%).from the former USSR (31%). In the other NTM group, most
of the patients (91%) were immigrants from Ethiopia (31%),
the Former Soviet Union (22%), and other countries (38%).
This difference was also statistically significant
(p Z 0.0001). There were no significant differences
between the groups in drug or alcohol use or smoking
status.
The two groups showed significant differences in pre-
senting symptoms. Chest pain, cough, and hemoptysis were
more common in patients with M. kansasii infection than in
patients with other NTM infections (Table 1). Past and
concurrent comorbid conditions are also shown in Table 1.
Significantly higher rates were noted in the Other NTM
group for malignancy (p Z 0.01), and old TB (p Z 0.003).Radiological features
Among patients with NTM other than M. kansasii, 5 (14.7%)
had normal chest radiographs as did 2 patients (3.1%) with
M. Kansasii infection, (p Z 0.013). All remaining patients
had findings of mycobacterial disease. Cavitary disease was
noted in 34 patients (53%) with M. kansasii infection and
only 2 patients (6%) with other NTM infections (pZ 0.0001).in patients infected with M. kansasii or other nontuberculous
Z 64 (%) Other NTM N Z 34 (%) P value
63  13 0.0001
20 (59) 0.611
14 (41)
3 (9) 0.0001
7 (22)
11 (31)
13 (38)
15 (43) 0.711
1 (4) 0.358
3 (10) 0.254
3 (9) 0.003
5 (15) 0.0005
4 (17) 0.001
11 (32) 0.890
70 (58) 0.028
14 (14) 0.493
1 (2.9) 0.851
2 (5.9) 0.538
0 (0) 0.260
2 (5.9) 0.032
5 (14.7) 0.324
4 (11.8) 0.957
8 (23.5) 0.003
0 (0) 0.254
1 (2.9) 0.462
Table 2 Radiological findings in patients infected with M. kansasii or other NTM.
M. kansasii N Z 64 Other NTMa N Z 34 P value
Normal chest x-ray 2 (3.1) 5 (14.7) 0.013
Infiltrates 33 (51.6) 12 (35.3) 0.410
Cavitation 34 (53.1) 2 (5.9) 0.0001
Location on chest x-ray
Right upper lobe 39 (60.1) 8 (23.5) 0.0001
Left upper lobe 20 (31.3) 12 (20) 0.001
Middle lobes 3 (4.7) 2 (5.9) 0.632
Lower lobes 1 (1.6) 4 (11.8) 0.018
Bilateral disease 3 (4.7) 7 (20.6) 0.013
Pleural effusion 2 (3.1) 1 (2.9) 0.887
Lymphadenopathy 1 (1.6) 1 (2.9) 0.532
Miliary pattern 0 (0) 0 (0) 0.128
a NTM Z nontuberculous mycobacteria.
Bold values signify P  0.05.
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differed between the groups (Table 2). Upper-lobe disease
was diagnosed in 39 patients (60%) with M. kansasii infec-
tion compared to 8 patients (23.5%) with other NTM infec-
tions (p Z 0.0001). Bilateral disease was noted in
association with other NTM infections (7 vs. 3 patients;
p Z 0.013).
Other radiological findings are presented in Table 2.
Pleural effusions, lymphadenopathy and miliary pattern
were seen in the minority of patients in both groups.
Treatment
The basic treatment regimen in both groups was rifampicin
(600 mg), ethambutol (25 mg/kg for the first 2 months, then
15 mg/kg), and clarithromycin (1000 mg/d) administered
daily for at least 12 months of negative sputum culture
results. Patients with resistant strains were treated
according to the susceptibility tests. All M. kansasii isolates
were sensitive to rifampicin, all but one isolate (borderline)
were sensitive to ethambutol and ofloxacin, and all but two
isolates (borderline) were sensitive to clarithromycin.
Sensitivity rates to ethionamide and cycloserine were 91%
and 94%, respectively, with one isolate resistant to each. A
high rate of resistance was noted for ciprofloxacin (33%)
and capreomycin (26 isolates, 74%); 2 isolates (6%) were
highly resistant to capreomycin. Among the NTM infections
other than M. kansasii, 66% and 36% were resistant to
ethambutol and ofloxacin, respectively and 77%, 84%, 64%
were sensitive to clarithromycin, ethionamide and cyclo-
serine, respectively. Of the patients with M. kansasii, 98%
were treated with the basic regimen compared to 39% in
the other NTM group.
Outcome
Follow-up ranged from 28 to 108 (mean 39) months. No
relapses were detected during the follow-up period in the
M. kansasii group. However, 6 (17.6%) patients had
a treatment failure (2 with M. avium, 2 with M. simiae, 1
with M. gordonae and 1 with M. abscesus). There were no
deaths in the M. kansasii group. Five patients in the OtherNTM group died, but none of the deaths was directly
related to mycobacterial disease (3 were due to cerebral
stroke and 2 to cardiac disease).
Discussion
This study is the largest to date that directly and system-
atically compared the clinical and radiologic features of M.
kansasii and other NTM infections. Our findings validate the
commonly assumed differences between these two groups.
We found that most patients with M. Kansasii were
younger, native-born Israelis, and had symptoms of chest
pain, cough, and hemoptysis compared to patients with
other NTM infections who tended to be older, immigrants,
with a history of old tuberculosis, and presented with
weight loss, fever, and sweating.
On radiological study, patients with M. kansasii infection
had more cavitations, unilateral disease, and a higher
likelihood of right upper lobe disease.
As noted, most patients in the M. kansasii group in our
series were either native-born Israelis or immigrants from
the former USSR (42% and 31%, respectively). In contrast,
patients with other NTM infections were mainly immigrants
(69%). This demographic difference could be due to the
geographic heterogeneity of the NTM species, racial/ethnic
differences between patient groups, an interaction with
relative frequencies of TB in the M. kansasii versus non-M.
kansasii groups, or some combination of these factors. This
study however, was not designed to address this issue.
Hemoptysis occurred in 42% of the M. kansasii group
patients, which is slightly higher than the rates of 20%e30%
reported in earlier studies.17,18 Hemoptysis in pulmonary
infections may be related to the degree of endobronchial
disease and the erosion of bronchial vessels by cavitation.
Although there are no available data on the relative inci-
dence of endobronchial disease, the reported incidence of
cavitation in M. kansasii infection is 57%,4,20e22 which is
close to our hemoptysis rate. It is noteworthy that cavita-
tions were much less common in patients with other NTM
infections.
Compared to patients with M. kansasii, patients with
other NTM were more likely to have a history of old
1476 A. Matveychuk et al.tuberculosis. This observation emphasizes the higher rate
of pre-existing lung disease, particularly old tuberculosis, in
NTM pulmonary infection compared to M. kansasii infec-
tion.3,17 In our series, there was a higher incidence of
history of tuberculosis only in those with other NTM infec-
tions and not in the M. kansasii group, although not
statistically significant (Table 2). This could be explained
partially by demographic changes. Moreover, NTM species
groups are less pathogenic than M. kansasii. So, the less
pathogenic organisms may require a greater reduction or
breach in the normal local host defenses that can be
provided in the presence of "old TB" with parenchymal
destruction. M. kansasii on the other hand is considered
a more pathogenic organism that can more readily establish
a significant infection in relatively normal lung tissue.
The radiographic features of NTM pulmonary infections
have been variably reported to be indistinguishable from
tuberculosis,23e25 highly suggestive of NTM infection,25e27
or quite different from M. tuberculosis infection.28,29
These discrepancies may be explained in part by the
different diagnostic methods used. Our study is the first to
compare the radiological features of M. kansasii and other
NTM infections and our radiologists were blinded to the
clinical data and the infecting organism. Our findings yiel-
ded several noteworthy differences. Importantly, all
patients had several radiological characteristics including
lack of lymphadenopathy, pleural effusion, and miliary
pattern in non-HIV population. The lack of pleural effusion
in other NTM infections is in accordance with the literature
on NTM.18e21 However, as noted above, M. kansasii infec-
tion was associated with cavitary infiltrates and a predi-
lection for upper lobe disease, whereas other NTM
infections were associated with noncavitary disease and
lower and middle lobe predominance. It should be kept in
mind, that others have recognized noncavitary lung disease
as part of the spectrum of M. kansasii infection,4,7 and that
in our series, cavitary disease occurred in 53% of the M.
kansasii group compared to 5.9% of the Other NTM group.
Although the radiographic picture of M. kansasii infections
was not pathognomonic, the disease usually occurred
unilaterally without a pleural component or
lymphadenopathy.
Our study found a high rate of upper lobe predominance
in NTM infections other than M. kansasii (23.5% and 20% in
the right and left upper lobes, respectively). These findings
are higher than those recently reported in North American
studies, where it is believed that a mid-zone, nodular,
bronchiectatic form of pulmonary NTM is more common.
This may be due to the high proportion of prior TB in this
population in our cohort.
Our study has several limitations, including retrospec-
tive design, use of medical records for data collection, and
radiological assessment based mainly on chest radiographs
and not CT scans. Additional, larger prospective studies will
be needed to corroborate our findings.Summary
The clinical and radiological appearance of M. kansasii and
other NTM infections differ significantly. Findings of lower
and middle lobe disease, pleural effusions, or mediastinallymphadenopathy make the diagnosis of M. kansasii infec-
tion very unlikely. NTM infections other than M. kansasii
appear to occur more often in older people, and are asso-
ciated with a lower rate of cough and hemoptysis at
presentation. Continuous surveys of mycobacterial species
and analyses of the clinical significance of these differences
are warranted.Conflict of interest statement
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